Navidea's Lymphoseek meets primary efficacy endpoint in Phase 3 trial Navidea announced the publication of results from two Phase 3 clinical trials of Lymphoseek (technetium 99m tilmanocept) Injection in patients with breast cancer. The trials assessed the performance of Lymphoseek against the standard of care, Vital Blue Dye, in lymphatic mapping. Results demonstrated that Lymphoseek met its primary efficacy endpoint of rate of agreement, or concordance, with VBD. Lymphoseek is a receptor-targeted radiopharmaceutical recently approved by the FDA and indicated for use in lymphatic mapping for breast cancer and melanoma.
News For NAVB From The Last 14 Days
Check below for free stories on NAVB the last two weeks.
Subscribe for More Information